1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Imagion Biosystems Limited

Imagion Biosystems Limited

IBXXF
Imagion Biosystems LimitedUS flagOther OTC
0.03
USD
- -
- -
6.63MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
0.03
0.05
0.01
0.01
0.02
0.04
0.03
- -
Basic EPS, GAAP
- -
-1.7
-1.42
-0.38
-0.29
-0.23
-0.35
-0.43
-0.05
-0.02
Free Cash Flow per Basic Share
- -
-0.08
-0.01
- -
- -
-0.01
-0.02
-0.01
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
1.27
0.34
0.25
0.61
0.41
0.04
-0.31
-0.1
-0.02
Tangible Book Value per Share
- -
1.52
0.66
0.33
0.69
0.51
0.17
-0.15
-0.05
-0.01
Basic Weighted Avg Shares
- -
5
6
9
19
26
28
30
45
277
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
1
- -
Operating Margin (%)
- -
-35,706.71
-4,677.93
-1,331.29
-3,767.37
-3,709.29
-2,583.06
-1,122.52
-194.15
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
- -
- -
Net Income, GAAP
- -
-8
-8
-3
-5
-6
-10
-13
-2
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-38,775.26
-4,355.62
-835.46
-2,607.47
-2,587.21
-2,071.53
-955.43
-178.15
- -
Working Capital
11
13
4
2
13
13
3
-6
-2
-2
LT Debt
- -
- -
- -
1
- -
- -
4
4
- -
- -
Total Equity
12
7
4
3
13
13
5
-5
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-91.43
-214.31
-162.36
-79.05
-54.51
-166.47
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-63.71%
-5.3%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
26.53%
108.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-0.43
2024
- -
- -
- -
- -
-0.05
2025
- -
- -
- -
- -
-0.02

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Robert Romeo Proulx
Full Time Employees
11
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Suite 2 Melbourne VIC Australia 3000
IPO Date
Sep 21, 2020
Website
imagionbiosystems.com
Similar Companies
Imagion Biosystems Limited (IBXXF)
Eurofins-Cerep S.A. (ALECR.PA)
Global Cord Blood Corporation (CO)
Clínica Baviera, S.A. (CBAV.MC)
Neogen Corporation (NEOG)
Invitae Corporation (NVTAQ)
Business
Imagion Biosystems Limited (IBXXF) develops non-invasive cancer detection technologies using magnetic nanoparticles and molecular MRI imaging. The company offers MagSense molecular MRI imaging agents, including MagSense HER2 for detecting and staging metastatic HER2-positive breast cancer in axillary lymph nodes; MagSense PSMA for prostate cancer detection to guide precision biopsies; MagSense FR for ovarian cancer targeting folate receptors; and PrecisionMRX iron oxide nanoparticles for magnetic relaxometry and biomedical applications; all integrated with standard MRI systems without ionizing radiation or radioactive tracers. Founded in 2016 and headquartered in Melbourne, Australia, with operations in San Diego, California, Imagion Biosystems targets oncology diagnostics for breast, prostate, and ovarian cancers served worldwide through research, development, and clinical collaborations. Recent developments include completion of a $3.5 million capital raising in August-September 2025 led by CPS Capital to fund an Investigational New Drug application submission to the U.S. FDA in Q4 2025 and initiation of a Phase 2 clinical trial for MagSense HER2; manufacturing of a new clinical lot of the MagSense HER2 imaging agent; positive FDA feedback supporting the Phase 2 plans; a new collaboration with Wayne State University for MRI protocol optimization alongside existing partnerships with Siemens Healthineers; and appointment of Dr. Nina Webster as non-executive director in September 2025.